Darifenacin: Pharmacology and clinical usage (Q30441757)

21 June 2017

1 reference

title

Darifenacin: Pharmacology and clinical usage (English)

1 reference

21 June 2017

1 reference

1

William D Steers

1 reference

21 June 2017

publication date

1 November 2006

1 reference

Urologic Clinics of North America

21 June 2017

published in

1 reference

21 June 2017

volume

33

1 reference

21 June 2017

issue

4

1 reference

21 June 2017

page(s)

475-82, viii

1 reference

Darifenacin: in the treatment of overactive bladder

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Urinary bladder contraction and relaxation: physiology and pathophysiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

M(3) muscarinic receptors mediate contraction of human urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Pharmacological Effects of Darifenacin on Human Isolated Urinary Bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Signal transduction underlying carbachol-induced contraction of human urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Muscarinic receptor subtypes in the human colon: lack of evidence for atypical subtypes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

M(3)-receptor knockout mice: muscarinic receptor function in atria, stomach fundus, urinary bladder, and trachea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Alteration of M(3) subtype muscarinic receptors in the diabetic rat urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Effect of muscarinic antagonists on micturition pressure measured by cystometry in normal, conscious rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Both M1 and M3 receptors regulate exocrine secretion by mucous acini

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Functional M3 muscarinic acetylcholine receptors in mammalian hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first‐pass metabolism, CYP2D6 genotype and formulation‐dependent bioavailability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Darifenacin in the treatment of overactive bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Which anticholinergic drug for overactive bladder symptoms in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

An investigation of dose titration with darifenacin, an M3-selective receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Increased warning time with darifenacin: a new concept in the management of urinary urgency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Role of hippocampal M2 muscarinic receptors in the estrogen-induced enhancement of working memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Oxybutynin disrupts learning and memory in the rat passive avoidance response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Tolterodine and memory: dry but forgetful

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Assessment of cognitive function of the elderly population: effects of darifenacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Preliminary communication: urodynamic assessment of donepezil hydrochloride in patients with Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

Current drug use as risk factor for erectile dysfunction: results from an Italian epidemiological study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.06.007

10.1016/J.UCL.2006.06.007

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference